{"address1": "194 Candelero Drive", "address2": "Suite 223", "city": "Humacao", "state": "PR", "zip": "00791", "country": "United States", "phone": "415 592 7399", "website": "https://aspirebiolabs.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Kraig T. Higginson", "age": 68, "title": "President, CEO & Chairman of Board", "yearBorn": 1956, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ernest J. Scheidemann Jr.", "age": 63, "title": "Chief Financial Officer", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen E. Quesenberry", "age": 60, "title": "General Counsel, Corporate Secretary & Director", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.0677, "open": 0.0572, "dayLow": 0.0677, "dayHigh": 0.0677, "regularMarketPreviousClose": 0.0677, "regularMarketOpen": 0.0572, "regularMarketDayLow": 0.0677, "regularMarketDayHigh": 0.0677, "beta": 0.366, "volume": 100, "regularMarketVolume": 100, "fiftyTwoWeekLow": 0.0677, "fiftyTwoWeekHigh": 0.0677, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "floatShares": 293607766, "bookValue": -0.002, "netIncomeToCommon": -648157, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.0677, "recommendationKey": "none", "totalCash": 16541, "totalCashPerShare": 0.0, "totalDebt": 853113, "quickRatio": 0.017, "currentRatio": 0.187, "operatingCashflow": -403451, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ASBPW", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.0677, "marketState": "PRE", "longName": "Aspire Biopharma Holdings, Inc.", "priceToBook": -33.85, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Aspire BioPharma, Inc.", "nameChangeDate": "2025-03-30", "cryptoTradeable": false, "hasPrePostMarketData": true, "regularMarketChange": 0.0, "regularMarketDayRange": "0.0677 - 0.0677", "fullExchangeName": "NasdaqCM", "fiftyTwoWeekLowChange": 0.0, "fiftyTwoWeekLowChangePercent": 0.0, "fiftyTwoWeekRange": "0.0677 - 0.0677", "fiftyTwoWeekHighChange": 0.0, "fiftyTwoWeekHighChangePercent": 0.0, "corporateActions": [], "regularMarketTime": 1743105600, "exchange": "NCM", "messageBoardId": "finmb_1860544308", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Aspire Biopharma", "trailingPegRatio": null}